During the corresponding time, Aim Immunotech Inc recorded a revenue increase by 37.5 % year on year, sequentially revenue grew by 4.76 %. While revenue at the Aim Immunotech Inc 's corporate clients
Aim Immunotech Inc's Comment on Sales, Marketing and Customers
AIM focuses on the oncology market, specifically targeting pancreatic cancer. Their pancreatic cancer program includes broad combination therapy patents and orphan drug designations in the US and EU. AIM is conducting clinical trials combining Ampligen with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer patients. The DURIPANC Phase 2 study is ongoing at Erasmus MC Cancer Institute in the Netherlands, evaluating clinical benefit, overall survival, progression-free survival, immune monitoring, and quality of life. AIM has partnered with Thermo Fisher Scientific's PPD clinical research business to design a Phase 3 trial for late-stage pancreatic cancer. Additionally, AIM and its Contract Research Organization, Amarex, submitted an IND application to the FDA for a Phase 2 study of Ampligen in locally advanced or metastatic pancreatic cancer. Ampligen also demonstrates potential efficacy in other solid tumors.
Ampligen: A Promising Player in the Fight Against Cancer and Viral Infections AIM ImmunoTech Inc. continues to push the frontiers in the field of immunotherapy, with a series of compelling announcements highlighting the utility of Ampligen (rintatolimod) in combating difficult-to-treat diseases. The latest revelations about Ampligen were showcased in a late-breaking abstract presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, held in National Harbor, MD, from November 5-9, 2025. Innovative Strategies in Ovarian Cancer Treatment Among the fascinating developments, AIM ImmunoTech has revealed data from a completed Phase 2 clinical study that investigated the effectiveness of Amplig...
Exploring the Potential of Ampligen in Alleviating Post-COVID Fatigue: AIM ImmunoTech s Promising Developments AIM ImmunoTech Inc. has recently completed a comprehensive analysis of clinical patient data related to its investigational drug, Ampligen (AMP-518), and the findings shed light on its potential benefits for individuals experiencing post-COVID fatigue. As the world emerges from the COVID-19 pandemic, a significant number of individuals are reporting lingering symptoms, particularly fatigue, which can severely impact quality of life. This condition, often referred to as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), poses a growing public health challenge, making AIM ImmunoTech s work particular...
AIM ImmunoTech, a specialized biopharmaceutical company focused on research and development, recently announced that the first dose level of their Phase 1b/2 study involving a combination therapy of Ampligen and Imfinzi was generally well-tolerated in late-stage pancreatic cancer patients. This innovative clinical trial is designed to evaluate the safety and effectiveness of this combination regimen, which might offer a new treatment avenue for patients with this notoriously difficult-to-treat disease.The study involves a safety cohort, i.e., a group of patients who are closely monitored for any side effects from the treatment. The company has announced that escalated dosing with the next safety cohort is se...
AIM ImmunoTech, a renowned biopharmaceutical company, continues to advance its clinical development pipeline, displaying remarkable progress across various Ampligen clinical programs. This article will outline the recent advancements made by AIM ImmunoTech and provide a business update. Additionally, we will analyze the revenue growth trends of the company, shedding light on the impact of these developments.AIM ImmunoTech s Clinical Development Pipeline:AIM ImmunoTech has been making significant strides in its clinical development programs, particularly in the field of Ampligen. Ampligen, the company s flagship therapeutic agent, is being evaluated for potential applications in various clinical settings, inc...
AIM ImmunoTech, a leading biopharmaceutical company, has announced the publication of exciting data from a Phase 1 study of Ampligen at the Roswell Park Comprehensive Cancer Center. The study evaluated the use of Ampligen as a component of a Chemokine-Modulating (CKM) regimen in patients with metastatic triple-negative breast cancer. Published in The Journal for ImmunoTherapy of Cancer, the study highlights the potential of Ampligen in treating this aggressive form of breast cancer. Additionally, Aim Immunotech Inc recorded a significant revenue increase of 40% year on year, demonstrating the company s growth and success. The Advancement in Breast Cancer Treatment: Triple-negative breast ca...
Aim Immunotech Inc’s Comment on Sales, Marketing and Customers
AIM focuses on the oncology market, specifically targeting pancreatic cancer. Their pancreatic cancer program includes broad combination therapy patents and orphan drug designations in the US and EU. AIM is conducting clinical trials combining Ampligen with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer patients. The DURIPANC Phase 2 study is ongoing at Erasmus MC Cancer Institute in the Netherlands, evaluating clinical benefit, overall survival, progression-free survival, immune monitoring, and quality of life. AIM has partnered with Thermo Fisher Scientific's PPD clinical research business to design a Phase 3 trial for late-stage pancreatic cancer. Additionally, AIM and its Contract Research Organization, Amarex, submitted an IND application to the FDA for a Phase 2 study of Ampligen in locally advanced or metastatic pancreatic cancer. Ampligen also demonstrates potential efficacy in other solid tumors.
Sources:
Aim Immunotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aim Immunotech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aim Immunotech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
